恒瑞医药：公司及子公司获得药物临床试验批准通知书

Core Viewpoint - 恒瑞医药 has received approval from the National Medical Products Administration for multiple clinical trial applications, indicating a significant advancement in its drug development pipeline [1][2]. Group 1: Company Developments - 恒瑞医药 and its subsidiaries have been granted clinical trial approval for several products, including HRS-4642 injection, SHR-1701 injection, and others, which will commence trials soon [1]. - The company's revenue composition for the year 2024 is projected to be 89.37% from pharmaceutical manufacturing and 10.63% from other businesses [1]. Group 2: Market Position - As of the latest report, 恒瑞医药's market capitalization stands at 410.2 billion yuan [2].